The Priority Review

Tag

Rare Thyroid Therapeutics International AB

1 story

Stories

  1. Regulation

    FDA issues priority review voucher for EMCITATE (tiratricol)

    The FDA announced that EMCITATE (tiratricol), approved September 28, 2026, manufactured by Rare Thyroid Therapeutics International AB, meets the criteria for a priority review voucher. The tablet is indicated for treating peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome).